SCHEMBL1160940

SCHEMBL1160940

CCN1Cc2c(Nc3cccc(Cl)c3)ccnc2NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 3/20 0.44
PTK6 Q13882 3/20 0.44
FADS1 O60427 1/20 0.43
GRM5 P41594 2/20 0.40
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39
ROCK1 Q13464 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
GRM4 Q14833 1/20 0.38
EGFR P00533 2/20 0.37
HPGD P15428 2/20 0.37
APP P05067 1/20 0.37
NR4A2 P43354 1/20 0.37
ENPP1 P22413 1/20 0.37
LMNA P02545 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029512 0.87 CDK4 (0.40) GRM5PTGS1PTGS2EGFRENPP1
SCHEMBL11026605 0.85 PTK6 (0.45) ERBB2PTK6PTGS1PTGS2GRM4
SCHEMBL1160764 0.85 AURKA (0.45) ERBB2PTK6PTGS1ROCK1EGFR
SCHEMBL11030109 0.83 PDGFRB (0.37) GRM4ENPP1
SCHEMBL11027540 0.82 JAK2 (0.43) ENPP1
SCHEMBL1161228 0.82 GRM4 (0.39) ERBB2PTK6GRM4EGFR
SCHEMBL11030262 0.81 BRD4 (0.42) PTK6EGFRENPP1
SCHEMBL1161157 0.80 IDH1 (0.42) PTGS1PTGS2EGFRENPP1ALDH1A1
SCHEMBL11027546 0.80 TYK2 (0.42) ENPP1TSHR
SCHEMBL1160852 0.80 PTGS1 (0.38) PTK6PTGS1PTGS2EGFRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
EP-2461869-B1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2013-08-21 EP disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
EP-2461869-A1 NOVEL BICYCLIC UREA COMPOUNDS Merck Patent GmbH (DE) 2012-06-13 EP disclosed
WO-2011017142-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed
WO-2011017142-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS CCNC, CCNI, CCNA1 ERBB2 1520/4885PTK6 3659/4885FADS1 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.